Variation of circulating tumor cell levels during treatment of metastatic breast cancer: Prognostic and therapeutic implications

Franco Nolé, E. Munzone, L. Zorzino, I. Minchella, M. Salvatici, E. Botteri, M. Medici, E. Verri, L. Adamoli, N. Rotmensz, A. Goldhirsch, M. T. Sandri

Research output: Contribution to journalArticlepeer-review

Abstract

Background: This study aimed to evaluate the prognostic significance of circulating tumor cells (CTCs) detection in advanced breast cancer patients. Patients and methods: We tested 80 patients for CTC levels before starting a new treatment and after 4, 8 weeks, at the first clinical evaluation and every 2 months thereafter. CTCs were detected using the CellSearch System™. Results: Forty-nine patients had ≥5 CTCs at baseline. At the multivariate analysis, baseline number of CTCs was significantly associated with progression-free survival [hazard ratio (HR) 2.5; 95% confidence interval (CI) 1.2-5.4]. The risk of progression for patients with CTCs ≥5 at last available blood draw was five times the risk of patients with 0-4 CTCs at the same time point (HR 5.3; 95% CI 2.8-10.4). Patients with rising or persistent ≥5 CTCs at last available blood draw showed a statistically significant higher risk of progression with respect to patients with

Original languageEnglish
Pages (from-to)891-897
Number of pages7
JournalAnnals of Oncology
Volume19
Issue number5
DOIs
Publication statusPublished - May 2008

Keywords

  • Advanced breast cancer
  • Breast cancer
  • Circulating tumor cells
  • Novel assay technology
  • Prognostic value
  • Tumor markers

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Variation of circulating tumor cell levels during treatment of metastatic breast cancer: Prognostic and therapeutic implications'. Together they form a unique fingerprint.

Cite this